Table of Contents As filed with the Securities and Exchange Commission on March 27, 2026. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER Delaware 3826 36-4899036 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) 47071 Bayside Parkway Fremont, California 94538 (510) 626-9888 (Address, including zip code, and telephone number, including area code, of registrant's principal execut ...

Core Insights - Alamar Biosciences has launched the NULISAseq Neuro 220 Panel, which allows for the multiplexed measurement of 220 biomarkers from a single sample, enhancing early detection capabilities for neurodegenerative diseases [1][2] Group 1: Product Launch and Features - The NULISAseq Neuro 220 Panel expands on the existing NULISAseq CNS Disease Panel 120, incorporating new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research [1][2] - The panel includes a comprehensive collection of Tau protein assays, targeting both brain-derived and peripheral isoforms, making it the largest suite of Tau assays available in a single panel [1][2] - The panel is designed for ultra-high sensitivity and high specificity, ensuring compatibility with non-invasive sample collection devices and supporting pre-symptomatic detection [2][4] Group 2: Research and Development Impact - The launch of the NULISAseq Neuro 220 Panel is expected to raise the standard for neurodegenerative disease research, applicable to a wide range of conditions including Alzheimer's, Parkinson's, and multiple sclerosis [2][4] - The panel facilitates the analysis of disease heterogeneity, detection of co-pathologies, and identification of prognostic or therapeutic response signatures across clinical cohorts [2][4] Group 3: Conference Presentation - The NULISAseq Neuro 220 Panel will be featured at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD 2026) in Copenhagen, Denmark, with data presentations scheduled [3][4] - Dr. Henrik Zetterberg will present data demonstrating the utility of the panel in neurodegenerative diseases during Alamar's product theater on March 18 [3]